Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: results from a phase 2b study with abrocitinib
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
EL Simpson, A Wollenberg, R Bissonnette…
…, 2021
journals.sagepub.com
Background Moderate-to-severe atopic dermatitis (AD) is inadequately controlled with current treatments for many patients. Abrocitinib is an oral Janus kinase 1 selective inhibitor under investigation for the treatment of AD. Objective The aim of the study was to evaluate patient-reported outcomes in a phase 2b study of abrocitinib in adults with moderate-to-severe AD inadequately controlled by topical therapy (NCT02780167). Methods Patients (N= 267) were randomly assigned 1: 1: 1: 1: 1 to 12-week, once-daily abrocitinib (200, 100 …
